Wednesday, 15 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 15 January 2025
News

AbbVie nabs potential blockbuster

Posted 4 December 2023 AM

AbbVie has made a huge buy to nab a first-in-class anti-body drug conjugate (ADC) approved for ovarian cancer and will accelerate its move into the market.

The pharma has signed a definitive agreement to buy US-based ImmunoGen for around $15 billion (US$10.1 billion), with the main attraction being Elahere - a first-in-class ADC which received approval to treat platinum-resistant ovarian cancer from the FDA in November 2022.

To see the whole article, please login

Popular

Pharmas ready to file new drugs
Four PBS listings kick off 2025
Guess who's scored a new job?
Govt skirts 'contempt' for pharma
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home